News & Updates

Statins reduce hepatocellular carcinoma risk in cirrhotic patients

17 Nov 2021

The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.

Statins reduce hepatocellular carcinoma risk in cirrhotic patients

17 Nov 2021

COVID toe: What does it tell you?

17 Nov 2021 by

New research suggests that COVID toe – a form of COVID-19–associated pernio or chilblains – may be a side effect of the immune system's response to fighting off the virus.

COVID toe: What does it tell you?

17 Nov 2021

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use

17 Nov 2021 by

In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who were receiving the novel nonsteroidal MRA* finerenone, use of SGLT-2is** at baseline did not influence treatment outcomes, according to a subgroup analysis of the FIDELITY*** trial presented at ASN 2021.

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use

17 Nov 2021

TAF rivals TDF for CHB suppression after orthotopic liver transplantation

17 Nov 2021 by

Switching from tenofovir disoproxil fumarate (TDF) regimens to tenofovir alafenamide (TAF) monotherapy demonstrates long-term efficacy and safety in orthotopic liver transplantation (OLT) recipients with chronic hepatitis B virus (HBV) infection, reports a study presented at The Liver Meeting Digital Experience 2021, by the American Association for the Study of Liver Diseases (AASLD 2021).

TAF rivals TDF for CHB suppression after orthotopic liver transplantation

17 Nov 2021

Original New Drug Application Approvals by US FDA (01-15 November 2021)

17 Nov 2021

New drug applications approved by US FDA as of 01-15 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 November 2021)

17 Nov 2021

Fenfluramine helps minimize day-to-day seizure burden in Dravet syndrome

17 Nov 2021

Treatment with fenfluramine in patients with Dravet syndrome (DS) appears to produce a marked reduction in day-to-day seizure burden and provide prolonged periods of convulsive seizure-free days, as shown in a study.

Fenfluramine helps minimize day-to-day seizure burden in Dravet syndrome

17 Nov 2021

Allergy testing during pregnancy could prevent unnecessary antibiotic exposure

16 Nov 2021 by

Women who have a documented history of penicillin allergy should undergo allergy tests during pregnancy to avoid exposure to potentially less effective broad-spectrum antibiotics, according to a small study presented at ACAAI 2021.

Allergy testing during pregnancy could prevent unnecessary antibiotic exposure

16 Nov 2021

SURTAVI: TAVR matches SAVR through 5 years in intermediate-risk AS patients

16 Nov 2021 by

The noninferiority finding between transcatheter vs surgical aortic valve replacement (TAVR vs SAVR) in intermediate-risk patients with severe aortic stenosis (AS) holds up through 5 years, according to long-term data of the SURTAVI trial presented at TCT 2021, providing reassurance that the less invasive procedure performs just as good in the elderly population.

SURTAVI: TAVR matches SAVR through 5 years in intermediate-risk AS patients

16 Nov 2021

Tenofovir alafenamide safe to use in breastfeeding mothers with CHB

16 Nov 2021 by

The first human pharmacokinetic study of tenofovir alafenamide (TAF; commercially sold as Vemlidy) monotherapy in breastfeeding women with chronic hepatitis B (CHB) has found low concentrations of TAF and tenofovir in the breastmilk, with negligible exposure to infants.

Tenofovir alafenamide safe to use in breastfeeding mothers with CHB

16 Nov 2021

Aspirin shows no therapeutic potential in ARDS

16 Nov 2021

In the treatment of patients with acute respiratory distress syndrome (ARDS), the use of aspirin improves neither oxygenation index nor other physiological outcomes, according to the results of a phase II study.

Aspirin shows no therapeutic potential in ARDS

16 Nov 2021

News & Updates

Filter by Specialty:

Specialty:

Statins reduce hepatocellular carcinoma risk in cirrhotic patients

Statins reduce hepatocellular carcinoma risk in cirrhotic patients

COVID toe: What does it tell you?

COVID toe: What does it tell you?

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use

TAF rivals TDF for CHB suppression after orthotopic liver transplantation

TAF rivals TDF for CHB suppression after orthotopic liver transplantation

Original New Drug Application Approvals by US FDA (01-15 November 2021)

Original New Drug Application Approvals by US FDA (01-15 November 2021)

Fenfluramine helps minimize day-to-day seizure burden in Dravet syndrome

Fenfluramine helps minimize day-to-day seizure burden in Dravet syndrome

Allergy testing during pregnancy could prevent unnecessary antibiotic exposure

Allergy testing during pregnancy could prevent unnecessary antibiotic exposure

SURTAVI: TAVR matches SAVR through 5 years in intermediate-risk AS patients

SURTAVI: TAVR matches SAVR through 5 years in intermediate-risk AS patients

Tenofovir alafenamide safe to use in breastfeeding mothers with CHB

Tenofovir alafenamide safe to use in breastfeeding mothers with CHB

Aspirin shows no therapeutic potential in ARDS

Aspirin shows no therapeutic potential in ARDS